Skip to main content

Table 2 Univariate analyses of predictors for pCR

From: Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer

Variable pCR (n = 75) Non-pCR (n = 248) Odds ratio (95% CI) P value
Age (years)
 ≤57 36 (48.0) 127 (51.2) Reference
 >57 39 (52.0) 121 (48.8) 1.137 (0.678–1.907) 0.626
Sex
 Male 44 (58.7) 130 (52.4) Reference
 Female 31 (41.3) 118 (47.6) 0.776 (0.460–1.309) 0.342
cT category
 2 7 (9.3) 19 (7.7) Reference
 3 58 (77.3) 176 (71.0) 0.894 (0.358–2.236) 0.811
 4 10 (13.3) 53 (21.4) 0.512 (0.171–1.537) 0.233
cN category
 N0 21 (28.0) 67 (27.0) Reference
 N1 35 (46.7) 126 (50.8) 0.886 (0.478–1.642) 0.701
 N2 19 (25.3) 55 (22.2) 1.102 (0.539–2.255) 0.790
cTNM classification
 II 21 (28.0) 67 (27.0) Reference
 III 54 (72.0) 181 (73.0) 0.952 (0.535–1.695) 0.867
Distance from the anal verge (cm)
 >5 44 (58.7) 156 (62.9) Reference
 ≤5 31 (41.3) 92 (37.1) 1.195 (0.705–2.023) 0.508
Pretreatment CEA (ng/mL)
 >5 18 (24.0) 103 (41.5) Reference
 ≤5 57 (76.0) 145 (58.5) 2.249 (1.251–4.046) 0.007
Tumor differentiation
 Well 6 (8.0) 18 (7.3) Reference
 Moderate 60 (80.0) 190 (76.6) 0.947 (0.360–2.495) 0.913
 Poor 9 (12.0) 40 (16.1) 0.675 (0.209–2.182) 0.511
Type of surgery
 Low anterior resection 40 (53.3) 150 (60.5) Reference
 Abdominoperineal resection 32 (42.7) 90 (36.3) 1.333 (0.782–2.273) 0.290
 Hartmann operation 3 (4.0) 8 (3.2) 1.406 (0.357–5.545) 0.626
Chemotherapy
 Capecitabine 61 (81.3) 206 (83.1) Reference
 Capecitabine + oxaliplatin 14 (18.7) 42 (16.9) 1.126 (0.577–2.198) 0.729
Time interval (weeks)
 ≤7 23 (30.7) 134 (54.0) Reference
 >7 52 (69.3) 114 (46.0) 2.658 (1.532–4.609) 0.001
Radiation dose (Gy)
 <50 4 (5.3) 14 (5.6) Reference
 =50 63 (84.0) 221(89.1) 0.998 (0.317–3.138) 0.997
 >50 8 (10.7) 13 (5.2) 2.154 (0.522–8.892) 0.289
  1. All values are presents as numbers of patients followed by percentages in parentheses. Other footnotes as in Table 1.
  2. CI confidence interval.